GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

by barry-jtcir | Jul 2, 2024 | Press Releases

Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice Compared to controls, mice treated with GRI-0621 showed histological...

GRI Bio to Present at the 8th Annual IPF Summit

by barry-jtcir | Jul 1, 2024 | Press Releases

LA JOLLA, CA, July 01, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory,...

GRI Bio Announces Closing of $4.0 Million Public Offering

by barry-jtcir | Jun 28, 2024 | Press Releases

LA JOLLA, CA, June 28, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory,...

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

by barry-jtcir | Jun 27, 2024 | Press Releases

Company is strategically building a global patent estate in key territories for a growing pipeline targeting potentially high-value indications in need of innovation LA JOLLA, CA, June 27, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...

GRI Bio Announces Pricing of $4 Million Public Offering

by barry-jtcir | Jun 27, 2024 | Press Releases

LA JOLLA, CA, June 27, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory,...